Generate Biomedicines, Inc. Common Stock (GENB) — Working Capital to Net Assets Ratio
Generate Biomedicines, Inc. Common Stock (GENB) has a Working Capital to Net Assets ratio of -24.4% as of December 2025. Working capital of $152.16 Million (current assets of $234.37 Million minus current liabilities of $82.20 Million) is measured against net assets of $-623.20 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Generate Biomedicines, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Generate Biomedicines, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Generate Biomedicines, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at -24.4%, reflecting working capital of $152.16 Million against net assets of $-623.20 Million USD. See GENB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Generate Biomedicines, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Generate Biomedicines, Inc. Common Stock market cap and net worth.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -24.4% | $152.16 Million | $-623.20 Million | $234.37 Million | $82.20 Million | ▲ +49.3 pp |
| 2024 | -73.7% | $320.87 Million | $-435.09 Million | $407.49 Million | $86.63 Million | — |